跳至主要内容
临床试验/NCT00064272
NCT00064272已完成2 期

Phase II Trial Of Encapsulized Ginger As A Treatment For Chemotherapy-Induced Nausea and Vomiting AKA IRB 2003-213

University of Michigan Rogel Cancer Center6 个研究点 分布在 2 个国家目标入组 180 人开始时间: 2003年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
180
试验地点
6
主要终点
Most efficacious dose

研究概览

简要总结

RATIONALE: The herb ginger may help to reduce or prevent nausea and vomiting in patients receiving chemotherapy for cancer.

PURPOSE: This randomized phase II trial is studying how well ginger works in reducing or preventing nausea and vomiting in patients who are receiving chemotherapy for cancer.

详细描述

OBJECTIVES:

Primary

  • Compare the prevalence and severity of delayed nausea and vomiting in patients with cancer undergoing chemotherapy treated with lower-dose ginger vs higher-dose ginger vs placebo.

Secondary

  • Compare the prevalence and severity of acute nausea and vomiting in patients treated with these regimens.
  • Compare the safety of these regimens in these patients.
  • Determine whether patients can determine if they are receiving placebo or study drug, and by which variable (e.g., taste, smell, or decrease in nausea and vomiting).

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Supportive Care
盲法
Double

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Arm I

Experimental

Patients receive lower-dose oral ginger twice daily.

干预措施: ginger extract (Drug)

Arm II

Experimental

Patients receive higher-dose oral ginger twice daily.

干预措施: ginger extract (Drug)

Arm III

Placebo Comparator

Patients receive oral placebo twice daily.

干预措施: placebo (Other)

结局指标

主要结局

Most efficacious dose

Ability to distinguish between receiving placebo or study drug and variables involved (e.g., taste, smell, or decrease in nausea and vomiting)

Safety

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (6)

Loading locations...

相似试验